

Who we are
We are a growing pharmaceutical company and a dedicated ally to healthcare providers treating patients facing rare conditions and emergencies.
Emergency Care: SERB has the broadest antidote portfolio in the world, including medical countermeasures for chemical, biological, radiological and nuclear (CBRN) risks. This makes us a trusted partner and one-stop-shop for hospitals, healthcare systems, first responders, emergency preparedness agencies, and non-profit organisations.
Rare Conditions: This growing portfolio helps patients with rare neurologic syndromes, metabolic disorders, and rare conditions in oncology. We work to help these patients get the diagnosis they need and access to the treatment options they deserve. This “patient first” culture has helped us to build long-term relationships with patient groups and key opinion leaders.
80+
Medicines
500+
dedicated employees
Direct sales in
18
countries
Supplying
100+
countries
An end-to-end platform
We are a fully integrated pharmaceutical company, but we remain agile and entrepreneurial.
Our goal is to optimise every stage of the pharma value chain through a perfect balance of in-house capabilities and closely managed external partners. Our unique industry expertise allows us to determine what to do ourselves and what to outsource to trusted partners. This allows us to efficiently acquire, develop, manufacture, launch and commercialize specialist medicines, and consistently supply them worldwide.
-
Sales and Marketing
Our global commercial platform is comprised of direct sales and marketing teams in key geographies: the US, Europe, and the Middle East. They have deep local knowledge and strong relationships with healthcare professionals, purchasing organisations, key opinion leaders, and patient associations. We reach healthcare providers in the rest of the world through a network of trusted distribution partners who share our expertise.
-
Delivering Innovation
We have a pipeline of R&D and lifecycle projects focused on areas of high unmet needs. These range from developing new products to expanding indications and registering our medicines in new markets. Our antibody platform offers unique opportunities to develop new antidotes and therapies, while other opportunities are explored through contract research organisations and independent investigators.
-
Business Development
Our business development team evaluate opportunities, facilitate quick decisions, and execute complex transactions. We have a track record of integration that ensures we unlock the full growth potential of acquired products, portfolios, and businesses. These capabilities allow us to offer prospective partners attractive value propositions, and creative deal structures. Read more about Partnering with SERB.
-
Quality Manufacturing
SERB has a hybrid approach to manufacturing. We have a best-in-class technological platform for the manufacture of polyclonal antibodies, with 4 manufacturing facilities located on three continents. Small and macro molecule manufacturing operations and logistics are outsourced to trusted European contract manufacturers with close oversight by our experienced in-house team.
-
Pharma Expertise
Our team of industry experts provide technical support for our in-house pharma operations and carefully manage our outsourced infrastructure. We have a unique and flexible set of capabilities in quality, regulatory, product registration, and pharmacovigilance. In addition to supporting our current portfolio, these professionals help to deliver R&D projects, perform due diligence, and integrate acquired assets.